{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T23:08:24Z","timestamp":1788736104682,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ctrv.2026.103182","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T06:50:55Z","timestamp":1783407055000},"page":"103182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Fusobacterium nucleatum and response to treatment in colon and rectal cancer: a systematic review"],"prefix":"10.1016","volume":"149","author":[{"given":"Sara","family":"De Dosso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Deantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giandomenica","family":"Iezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Christoforidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Vannelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milo","family":"Frattini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Garo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ctrv.2026.103182_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103182_bb0010","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S1470-2045(10)70172-8","article-title":"Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data","volume":"11","author":"Maas","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103182_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104974","article-title":"Gut microbiota and chemoradiotherapy response in rectal cancer: biomarker opportunities","volume":"216","author":"Taoum","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ctrv.2026.103182_bb0020","doi-asserted-by":"crossref","first-page":"1611300","DOI":"10.3389\/pore.2023.1611300","article-title":"Influence of the microbiota on the effectiveness and toxicity of oncological therapies, with a focus on chemotherapy","volume":"29","author":"Cazzaniga","year":"2023","journal-title":"Pathol Oncol Res"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103182_bb0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1002533","article-title":"Revised estimates for the number of human and Bacteria cells in the body","volume":"14","author":"Sender","year":"2016","journal-title":"PLoS Biol"},{"key":"10.1016\/j.ctrv.2026.103182_bb0030","article-title":"Association of Fusobacterium nucleatum with colorectal cancer molecular subtypes and its outcome: a systematic review","volume":"6","author":"Greco","year":"2025","journal-title":"Gut Microbiome (Camb)"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103182_bb0035","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s12672-025-04367-1","article-title":"The gut microbiome in colorectal cancer: mechanisms of carcinogenesis and emerging microbiota-targeted therapies","volume":"17","author":"Li","year":"2026","journal-title":"Discov Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103182_bb0040","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.cell.2017.07.008","article-title":"Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy","volume":"170","author":"Yu","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103182_bb0045","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13046-018-0985-y","article-title":"Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer","volume":"38","author":"Zhang","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103182_bb0050","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2024.2333790","article-title":"Fusobacterium nucleatum induces chemoresistance in colorectal cancer by inhibiting pyroptosis via the hippo pathway","volume":"16","author":"Wang","year":"2024","journal-title":"Gut Microbes"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103182_bb0055","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.immuni.2015.01.010","article-title":"Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack","volume":"42","author":"Gur","year":"2015","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103182_bb0060","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.ccell.2024.08.019","article-title":"Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer","volume":"42","author":"Wang","year":"2024","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103182_bb0065","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.chom.2026.02.006","article-title":"Intratumoral microbiota and host genotype cooperatively shape neutrophil cytotoxic functions in colorectal cancer","volume":"34","author":"Sorrenti","year":"2026","journal-title":"Cell Host Microbe"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103182_bb0070","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1136\/gutjnl-2015-310101","article-title":"Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis","volume":"65","author":"Mima","year":"2016","journal-title":"Gut"},{"issue":"39","key":"10.1016\/j.ctrv.2026.103182_bb0075","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000017221","article-title":"Prognostic impact of the Fusobacterium nucleatum status in colorectal cancers","volume":"98","author":"Chen","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103182_bb0080","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s10096-019-03649-1","article-title":"Fusobacterium nucleatum tumor DNA levels are associated with survival in colorectal cancer patients","volume":"38","author":"Kunzmann","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103182_bb0085","doi-asserted-by":"crossref","first-page":"796","DOI":"10.4103\/jcrt.jcrt_38_24","article-title":"Prognostic impact of Fusobacterium nucleatum on survival in colorectal cancer: a systematic review and meta-analysis","volume":"21","author":"Wang","year":"2025","journal-title":"J Cancer Res Ther"},{"key":"10.1016\/j.ctrv.2026.103182_bb0090","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ctrv.2026.103182_bb0095","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"issue":"7650","key":"10.1016\/j.ctrv.2026.103182_bb0100","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"Bmj"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103182_bb0105","article-title":"Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib\/II clinical trial and gut microbiome analysis","volume":"2","author":"Wang","year":"2021","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103182_bb0110","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2465015","article-title":"Combined tumor-associated microbiome and immune gene expression profiling predict response to neoadjuvant chemo-radiotherapy in locally advanced rectal cancer","volume":"14","author":"Roesel","year":"2025","journal-title":"Oncoimmunology"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103182_bb0115","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.annonc.2020.06.003","article-title":"Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer","volume":"31","author":"Serna","year":"2020","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103182_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071808","article-title":"Genomic and transcriptomic characterisation of response to neoadjuvant chemoradiotherapy in locally advanced rectal Cancer","volume":"12","author":"Toomey","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103182_bb0125","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/SLA.0000000000006015","article-title":"Young-onset rectal Cancer: unique tumoral microbiome and correlation with response to neoadjuvant therapy","volume":"278","author":"White","year":"2023","journal-title":"Ann Surg"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103182_bb0130","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1158\/1078-0432.CCR-20-3445","article-title":"Gut microbiome components predict response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a prospective, longitudinal study","volume":"27","author":"Yi","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103182_bb0135","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41392-021-00795-x","article-title":"Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer","volume":"6","author":"Gao","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103182_bb0140","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.chom.2023.04.010","article-title":"Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer","volume":"31","author":"Jiang","year":"2023","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ctrv.2026.103182_bb0145","article-title":"Gut microbiota composition in chemotherapy and targeted therapy of patients with metastatic colorectal cancer","volume":"12","author":"Chen","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103182_bb0150","doi-asserted-by":"crossref","first-page":"40","DOI":"10.4132\/jptm.2018.11.29","article-title":"Prognostic impact of Fusobacterium nucleatum depends on combined tumor location and microsatellite instability status in stage II\/III colorectal cancers treated with adjuvant chemotherapy","volume":"53","author":"Oh","year":"2019","journal-title":"J Pathol Transl Med"},{"key":"10.1016\/j.ctrv.2026.103182_bb0155","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.2147\/OTT.S145949","article-title":"Clinical significance of Fusobacterium nucleatum, epithelial-mesenchymal transition, and cancer stem cell markers in stage III\/IV colorectal cancer patients","volume":"10","author":"Yan","year":"2017","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.ctrv.2026.103182_bb0160","series-title":"Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy","author":"M.D. Anderson Cancer Center","year":"2026"},{"key":"10.1016\/j.ctrv.2026.103182_bb0165","article-title":"Preoperative metronidazole treatment to evaluate its efficacy in reducing Fusobacterium nucleatum colonisation in colorectal cancer patients: a proof-of-concept trial","volume":"8","author":"De Dosso","year":"2025","journal-title":"ESMO Gastrointest Oncol"},{"key":"10.1016\/j.ctrv.2026.103182_bb0170","series-title":"Metronidazole as Preoperative Therapy in CRC \/ FusoMetro-001","author":"Oncology Institute of Southern Switzerland","year":"2025"},{"key":"10.1016\/j.ctrv.2026.103182_bb0175","series-title":"Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer","author":"Virginia Commonwealth University","year":"2026"},{"key":"10.1016\/j.ctrv.2026.103182_bb0180","series-title":"Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial","author":"Fang","year":"2026"},{"key":"10.1016\/j.ctrv.2026.103182_bb0185","series-title":"Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT","author":"M.D. Anderson Cancer Center","year":"2026"},{"key":"10.1016\/j.ctrv.2026.103182_bb0190","series-title":"Fecal Microbiota Transplant (FMT) Capsule for Improving the Efficacy of Anti- PD-1","author":"Peking University","year":"2024"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000964?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000964?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T22:27:59Z","timestamp":1788733679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226000964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":38,"alternative-id":["S0305737226000964"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103182","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fusobacterium nucleatum and response to treatment in colon and rectal cancer: a systematic review","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103182","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103182"}}